Latest »
Seventh Closed Scientific Expert Meeting of the Editorial Board
ApoC3 as a therapeutic target for treatment of severe hypertriglyceridaemia (i) Plozasiran
Daniel Gaudet, Université de Montréal, Quebec, Canada, discusses recent results from the SHASTA-2 study of plozasiran in patients with severe hypertriglyceridaemia (SHTG) and the MUIR study of plozasiran in patients with mixed dyslipidaemia. He provides an update on the ongoing PALISADE study in familial chylomicronaemia syndrome, and the SHASTA-3 and SHASTA-4 studies in SHTG.
Watch the presentation
ApoC3 as a therapeutic target for treatment of severe hypertriglyceridaemia (ii) Olezarsen
Sam Tsimikas, University of California, San Diego, and Ionis Pharmaceuticals, USA, looks at the impact of apoC3 inhibition on triglyceride levels and acute pancreatitis reported in studies of volanesorsen and olezarsen, including topline results of the Balance study of
olezarsen in familial chylomicronaemia syndrome, and he looks at progress with the Bridge-TMI 73a, Essence and CORE and CORE2 studies.
Watch the presentation
Therapeutic options for the severely hypertriglyceridaemic patient: Now and in the future
Pamela Bowe Morris, Medical University of South Carolina, Charleston, USA, explains that severe hypertriglyceridaemia can be frustrating to manage, as success depends mainly on patient adherence to lifestyle recommendations, and TG-lowering agents are limited in availability, efficacy and tolerability. Emerging agents include volanesorsen, plozasiran, olezarsen, zodasiran and pegozafermin.
Watch the presentation
Expert commentaries
Triglyceride metabolism and mortality: What is the link?
Higher rates of triglyceride metabolism have recently been linked to increased all-cause, cardiovascular, cancer, and other mortality, but what does it mean for practising clinicians? Professor Børge G. Nordestgaard (University of Copenhagen, Denmark) discusses the new findings and their potential implications.
Read the commentary
Are remnants more atherogenic than LDL? Novel genetic insights
Elias Björnson, University of Gothenburg, Sweden, discusses data from a UK Biobank Study which investigated the association between triglyceride-rich lipoproteins/remnant cholesterol and risk of coronary heart disease, and the atherogenicity of those particles compared to low-density lipoprotein particles.
Read the commentary
Akira Endo, discoverer of statins, remembered
Akira Endo, the Japanese scientist universally recognised as the discoverer of statins, died on June 5 at the age of 90. The medical importance of his discovery is arguably comparable with Fleming’s discovery of penicillin.
Read more
Third Closed Scientific Expert Meeting of the Editorial Board
Keynote: What have we learned from triglyceride lowering trials using fibrates over the past 40 years?
Professor Marja-Riitta Taskinen reviews the evidence from the FIELD and ACCORD clinical trials in type 2 diabetes and considers how treatment might be tailored to patients most likely to benefit.
Novel PPAR agonists as therapeutics in hypertriglyceridaemia
Professor Bart Staels discusses latest understanding of the mechanisms of action of PPAR agonists, together with pre-clinical and clinical data on the selective PPARα modulator, pemafibrate.
Expert Commentaries
Triglyceride-rich lipoproteins and their remnants: Commentary on the 2021 EAS Consensus Statement
Professor Gary Lewis (University of Toronto, Canada) discusses the evidence presented in the 2021 EAS Consensus Statement and its implications for clinicians and patients.
ASCVD risk with persistent hypertriglyceridaemia: What is the latest guidance from ACC?
Dr Michael Miller (University of Maryland, Baltimore, USA) discusses the background to the latest ACC guidance and the recommendation to stratify patients for treatment according to their residual LDL-cholesterol level.
Clinical trials of innovative therapeutics
New insights into the biology of triglyceride metabolism underpin the development of novel therapies for managing hypertriglyceridaemia to reduce the risk of atherosclerotic cardiovascular disease (ASCVD) and, for severely elevated levels, pancreatitis.
In the last decade epidemiology and genetic studies – in particular, Mendelian randomisation studies – have moved the field forward and we are on the cusp of a new era in managing elevated triglycerides.
Major outcomes studies with these new therapies are fundamental to answering the much-debated question: Does lowering elevated triglycerides reduce residual cardiovascular risk?
About Triglyceride Forum
The Triglyceride Forum is a unique, independent, expert-led global initiative to address the rapidly evolving field of triglycerides and triglyceride-rich lipoproteins in cardiovascular disease and pancreatitis. This Forum will provide clinicians and researchers with international, open access, peer-reviewed resources at an important time when new and innovative molecules are at advanced stages of development… Read more >>
Why join?
Professors Ginsberg and Chapman explain the fundamental scientific and clinical research that has turned the spotlight on triglyceride-rich lipoproteins and their remnants as important players in the development of atherosclerotic CVD and pancreatitis and as targets for novel therapies for both these serious diseases.
FREE MEMBERSHIP
Join the Triglyceride Forum for open access to independent, evidence based knowledge and high quality educational programmes
View invitation from Henry Ginsberg
Join the Triglyceride Forum to share new data and exchange opinions with clinicians and researchers around the world
View invitation from John Chapman
Meet our Steering Committee
MAKING THE CONNECTION: TRIGLYCERIDES, RESIDUAL CV RISK AND PANCREATITIS
This unique, downloadable slide deck developed specially for Triglyceride Forum is a state-of-the-art guide to triglycerides and their association with residual cardiovascular risk and pancreatitis.
Why triglycerides now?
From the editors
Educational partners and supporters
